The pharmacological and physiological role of multidrug-resistant protein 4

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 3, 2015, Pages 358-375

  Wen, Jiagen ^b,c   Luo, Jianquan ^b,c   Huang, Weihua ^b,c   Tang, Jie ^b,c   Zhou, Honghao ^b,c   Zhang, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Key Laboratory of Pharmacogenetics ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CEPHALOSPORIN; DANTROLENE; DILAZEP; DIPYRIDAMOLE; EFAVIRENZ; FLAVONOID; FOLINIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LATANOPROST; MERCAPTOPURINE; METHOTREXATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PHOSPHODIESTERASE INHIBITOR; PROBENECID; TENOFOVIR; TIOGUANINE; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VERLUKAST; ZIDOVUDINE; ABC TRANSPORTER; DRUG; MULTIDRUG RESISTANCE PROTEIN;

ABCC4 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR FUNCTION; CEREBROVASCULAR ACCIDENT; CHILDHOOD LEUKEMIA; COLORECTAL CARCINOMA; COPY NUMBER VARIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EVENT FREE SURVIVAL; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC RISK; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; INOTROPISM; INTRAOCULAR HYPERTENSION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MRP4 GENE; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RADIOSENSITIVITY; RETINA NEOVASCULARIZATION; REVIEW; RNA INTERFERENCE; RNA SPLICING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; THROMBOCYTE AGGREGATION; TRANSCRIPTION REGULATION; ANIMAL; METABOLISM; NEOPLASM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION;

EID: 84941591671     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.225656     Document Type: Review

References (192)

1. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, and Ferrin TE, et al. (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325:859-868.
2. Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G, and Peters GJ (2014) Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus 3:732.
3. Anderson PL, Lamba J, Aquilante CL, Schuetz E, and Fletcher CV (2006) Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIVinfected adults: A pilot study. J Acquir Immune Defic Syndr 42:441-449.
4. Ansari M, Sauty G, Labuda M, Gagné V, Laverdière C, Moghrabi A, Sinnett D, and Krajinovic M (2009) Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 114:1383-1386.
5. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, and Evans RM, et al. (2004) Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279:22250-22257.
6. Bagnoli M, Beretta GL, Gatti L, Pilotti S, Alberti P, Tarantino E, Barbareschi M, Canevari S, Mezzanzanica D, and Perego P (2013) Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma. BioMed Res Int 2013:143202.
7. Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T, Sasaki M, Saito Y, and Fujiyama Y (2010) The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 45:1014-1021.
8. Banerjee M, Carew MW, Roggenbeck BA, Whitlock BD, Naranmandura H, Le XC, and Leslie EM (2014) A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII). Mol Pharmacol 86:168-179.
9. Battersby S, Sales KJ, Williams AR, Anderson RA, Gardner S, and Jabbour HN (2007) Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptormediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Hum Reprod 22:36-44.
10. Battistella M and Marsden PA (2015) Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference. Clin Pharmacol Ther 97: 79-87.
11. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, and Gallo JM, et al. (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogueinduced damage. Cancer Res 67:262-268.
12. Beretta GL, Benedetti V, Cossa G, Assaraf YG, Bram E, Gatti L, Corna E, Carenini N, Colangelo D, and Howell SB, et al. (2010) Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol 79:1108-1117.
13. Bickel M, Khaykin P, Stephan C, Schmidt K, Buettner M, Amann K, Lutz T, Gute P, Haberl A, and Geiger H, et al. (2013) Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med 14:633-638.
14. Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, and Konstantinova P; Réseau Centre de Ressources Biologiques Foie (French Liver Biobanks Network), France (2012) Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55:821-832.
15. Borgognone A and Pulcinelli FM (2012) Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport. Thromb Haemost 108: 955-962.
16. Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
17. Boutros T, Chevet E, and Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer. Pharmacol Rev 60:261-310.
18. Bröderdorf S, Zang S, Schaletzki Y, Grube M, Kroemer HK, and Jedlitschky G (2014) cAMP regulates expression of the cyclic nucleotide transporter MRP4 (ABCC4) through the EPAC pathway. Pharmacogenet Genomics 24:522-526.
19. Brüggemann M, Trautmann H, Hoelzer D, Kneba M, Gökbuget N, and Raff T (2009) Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia. Blood 114:5400-5401, author reply 5401-5402.
20. Cai C, Omwancha J, Hsieh CL, and Shemshedini L (2007) Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer Prostatic Dis 10:39-45.
21. Carillion A, Feldman S, Jiang C, Atassi F, Na N, Mougenot N, Besse S, Hulot JS, Riou B, and Amour J (2015) Overexpression of cyclic adenosine monophosphate effluent protein MRP4 induces an altered response to b-adrenergic stimulation in the senescent rat heart. Anesthesiology 122:334-342.
22. Carozzo A, Diez F, Gomez N, Cabrera M, Shayo C, Davio C, and Fernández N (2015) Dual role of cAMP in the transcriptional regulation of multidrug resistanceassociated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines. PLoS One 10: E0120651.
23. Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, Menter DG, Logsdon CD, and Ramachandran V (2013) PGE2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas 42:467-474.
24. Chaudhuri A, Kolodecik TR, and Gorelick FS (2005) Effects of increased intracellular cAMP on carbachol-stimulated zymogen activation, secretion, and injury in the pancreatic acinar cell. Am J Physiol Gastrointest Liver Physiol 288:G235-G243.
25. Chen L, Gu J, Xu L, Qu C, Zhang Y, and Zhang W (2014) RNAi-mediated silencing of ATP-binding cassette C4 protein inhibits cell growth in MGC80-3 gastric cancer cell lines. Cell Mol Biol (Noisy-le-grand) 60:1-5.
26. Chen ZS, Lee K, and Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17- b-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276:33747-33754.
27. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62: 3144-3150.
28. Cheung L, Flemming CL, Watt F, Masada N, Yu DM, Huynh T, Conseil G, Tivnan A, Polinsky A, and Gudkov AV, et al. (2014) High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochem Pharmacol 91:97-108.
29. Cheung L, Yu DM, Neiron Z, Failes TW, Arndt GM, and Fletcher JI (2015) Identification of new MRP4 inhibitors from a library of FDA approved drugs using a highthroughput bioluminescence screen. Biochem Pharmacol 93:380-388.
30. Chinen T, Komai K, Muto G, Morita R, Inoue N, Yoshida H, Sekiya T, Yoshida R, Nakamura K, and Takayanagi R, et al. (2011) Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun 2:190.
31. Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol 71:1591-1597.
32. Copsel S, Bruzzone A, May M, Beyrath J, Wargon V, Cany J, Russel FG, Shayo C, and Davio C (2014) Multidrug resistance protein 4/ATP binding cassette transporter 4: A new potential therapeutic target for acutemyeloid leukemia. Oncotarget 5:9308-9321.
33. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG, Russel FG, Shayo C, and Davio C (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979-6988.
34. Cowlen MS and Eling TE (1992) Modulation of c-jun and jun-B messenger RNA and inhibition of DNA synthesis by prostaglandin E2 in Syrian hamster embryo cells. Cancer Res 52:6912-6916.
35. Crean D, Bellwon P, Aschauer L, Limonciel A, Moenks K, Hewitt P, Schmidt T, Herrgen K, Dekant W, and Lukas A, et al. (2014) Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing. Toxicol In Vitro DOI:10.1016/j.tiv.2014.11.015 [published ahead of print].
36. Dean M, Rzhetsky A, and Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166.
37. de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, and Oude Elferink RP (2012) Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos 40:515-521.
38. Ding YB, Shi RH, Tong JD, Li XY, Zhang GX, Xiao WM, Yang JG, Bao Y, Wu J, and Yan ZG, et al. (2005) PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp Oncol 27:108-113.
39. Dreyling KW, Hoppe U, Peskar BA, Morgenroth K, Kozuschek W, and Peskar BM (1986) Leukotriene synthesis by human gastrointestinal tissues. Biochim Biophys Acta 878:184-193.
40. Dumaz N and Marais R (2003) Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 278: 29819-29823.
41. El-Sheikh AA, Koenderink JB, Wouterse AC, van den Broek PH, Verweij VG, Masereeuw R, and Russel FG (2014) Renal glucuronidation and multidrug resistance protein 2-/multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. Transl Res 164:46-56.
42. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- And MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320:229-235.
43. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2008a) Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 155:1066-1075.
44. El-Sheikh AA, van den Heuvel JJ, Krieger E, Russel FG, and Koenderink JB (2008b) Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol Pharmacol 74:964-971.
45. Fabricius D, Neubauer M, Mandel B, Schütz C, Viardot A, Vollmer A, Jahrsdörfer B, and Debatin KM (2010) Prostaglandin E2 inhibits IFN-a secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol 184:677-684.
46. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, and Selgas R, et al. (2011) Tenofovir nephrotoxicity: 2011 update. Aids Res Treat 2011:354908.
47. Ferslew BC, Köck K, Bridges AS, and Brouwer KL (2014) Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat. Drug Metab Dispos 42:1567-1574.
48. Friedman DL (1976) Role of cyclic nucleotides in cell growth and differentiation. Physiol Rev 56:652-708.
49. Fukuda Y, Takenaka K, Sparreboom A, Cheepala SB, Wu CP, Ekins S, Ambudkar SV, and Schuetz JD (2013) Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: A basis for unanticipated enhanced cytotoxicity. Mol Pharmacol 84:361-371.
50. Furugen A, Yamaguchi H, Tanaka N, Shiida N, Ogura J, Kobayashi M, and Iseki K (2013) Contribution of multidrug resistance-associated proteins (MRPs) to the release of prostanoids from A549 cells. Prostaglandins Other Lipid Mediat 106:37-44.
51. Ganapathy V, Gurlo T, Jarstadmarken HO, and von Grafenstein H (2000) Regulation of TCR-induced IFN-g release from islet-reactive non-obese diabetic CD81 T cells by prostaglandin E2 receptor signaling. Int Immunol 12:851-860.
52. Gao LC, Wang D, Liu FQ, Huang ZY, Huang HG, Wang GH, Chen X, Shi QZ, Hong L, and Wu LP, et al. (2015) Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients. Eur J Clin Pharmacol 71:43-50.
53. Gori I, Rodriguez Y, Pellegrini C, Achtari C, Hornung D, Chardonnens E, Wunder D, FicheM, and Canny GO (2013) Augmented epithelial multidrug resistance-associated protein 4 expression in peritoneal endometriosis: Regulation by lipoxin A4. Fertil Steril 99:1965-1973.e2.
54. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, and Bachmakov I, et al. (2008) Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8:42-52.
55. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, and Fan F, et al. (2008) Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 27:7192-7200.
56. Guo Y, Kock K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, and Siegmund W, et al. (2009) Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: Relation to long-term survival. Clin Cancer Res 15:1762-1769.
57. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, and Coleman RL, et al. (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12:4916-4924.
58. Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol 18:37-45.
59. Hayashi H, Naoi S, Nakagawa T, Nishikawa T, Fukuda H, Imajoh-Ohmi S, Kondo A, Kubo K, Yabuki T, and Hattori A, et al. (2012) Sorting nexin 27 interacts with multidrug resistance-associated protein 4 (MRP4) and mediates internalization of MRP4. J Biol Chem 287:15054-15065.
60. He Z, Hu B, Tang L, Zheng S, Sun Y, Sheng Z, Yao Y, and Lin F (2015) The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells. J Cancer Res Ther 11:18-23.
61. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, and Fletcher JI, et al. (2011) ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 103:1236-1251.
62. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, and Horvath LG (2008) Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 68:1421-1429.
63. Hoque MT and Cole SP (2008) Down-regulation of Na1/H1 exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4. Cancer Res 68:4802-4809.
64. Hoque MT, Conseil G, and Cole SP (2009) Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. Biochem Biophys Res Commun 379:60-64.
65. Huynh T, Norris MD, Haber M, and Henderson MJ (2012) ABCC4/MRP4: A MYCNregulated transporter and potential therapeutic target in neuroblastoma. Front Oncol 2:178.
66. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, and Nakajima A (2007) Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 103:24-32.
67. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71:619-627.
68. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, and Ciullo I, et al. (1997) Activation of cAMPPKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med 3:775-779.
69. Izzedine H, Kheder-Elfekih R, Housset P, Sarkozy C, Brocheriou I, and Deray G (2009) Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 23:544-545.
70. Jain S, Chakraborty G, Raja R, Kale S, and Kundu GC (2008) Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 68:7750-7759.
71. James CW, Steinhaus MC, Szabo S, and Dressier RM (2004) Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 24:415-418.
72. Jedlitschky G, Cattaneo M, Lubenow LE, Rosskopf D, Lecchi A, Artoni A, Motta G, Niessen J, Kroemer HK, and Greinacher A (2010) Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: Evidence from patients with delta-storage pool deficiencies. Am J Pathol 176:1097-1103.
73. Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A, and Kroemer HK (2004) The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104:3603-3610.
74. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, and Krajcsi P (2010) ABCC2/Abcc2: A multispecific transporter with dominant excretory functions. Drug Metab Rev 42:402-436.
75. Kang KW, Im YB, Go WJ, and Han HK (2009) c-Myc amplification altered the gene expression of ABC- And SLC-transporters in human breast epithelial cells. Mol Pharm 6:627-633.
76. Kato JY, Matsuoka M, Polyak K, Massagué J, and Sherr CJ (1994) Cyclic AMPinduced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487-496.
77. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, and Fletcher CV (2008a) Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 47:298-303.
78. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, and Fletcher CV (2008b) The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83:265-272.
79. Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, and Brouwer KL (2014) Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42:665-674.
80. Kolodecik TR, Shugrue CA, Thrower EC, Levin LR, Buck J, and Gorelick FS (2012) Activation of soluble adenylyl cyclase protects against secretagogue stimulated zymogen activation in rat pancreaic acinar cells. PLoS One 7:e41320.
81. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
82. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, and Nakauchi H, et al. (2008) Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68:4983-4989.
83. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, and Dubinett SM (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65: 6275-6281.
84. Kuiperij HB, van der Horst A, Raaijmakers J, Weijzen S, Medema RH, Bos JL, Burgering BM, and Zwartkruis FJ (2005) Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP. Oncogene 24:2087-2095.
85. L'Allemain G, Lavoie JN, Rivard N, Baldin V, and Pouyssegur J (1997) Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene 14:1981-1990.
86. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez- Berestein G, and Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910-6918.
87. Larré S, Tran N, Fan C, Hamadeh H, Champigneulles J, Azzouzi R, Cussenot O, Mangin P, and Olivier JL (2008) PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat 87:14-19.
88. Lee K, Klein-Szanto AJ, and Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92:1934-1940.
89. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, and Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621.
90. Lemos Legnazzi B, Shayo C, Monczor F, Martin ME, Fernandez N, Brodsky A, Baldi A, and Davio C (2000) Rapid desensitization and slow recovery of the cyclic AMP response mediated by histamine H2 receptors in the U937 cell line. Biochem Pharmacol 60:159-166.
91. Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, and Schuetz JD, et al. (2007) Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131: 940-951.
92. Li SP, Chen XJ, Sun AH, Zhao JF, and Yan J (2010) CagA1 H. pylori induces Akt1 phosphorylation and inhibits transcription of p21WAF1/CIP1 and p27KIP1 via PI3K/Akt1 pathway. Biomed Environ Sci 23:273-278.
93. Li X, Zhou G, Zhou X, and Zhou S (2013) The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of randomized controlled trials. J Neurol Sci 332:92-96.
94. Lien LM, Chen ZC, Chung CL, Yen TL, Chiu HC, Chou DS, Huang SY, Sheu JR, Lu WJ, and Lin KH (2014) Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo. Eur J Pharmacol 737:159-167.
95. Liu D, Huang Y, Bu D, Liu AD, Holmberg L, Jia Y, Tang C, Du J, and Jin H (2014) Sulfur dioxide inhibits vascular smooth muscle cell proliferation via suppressing the Erk/MAP kinase pathway mediated by cAMP/PKA signaling. Cell Death Dis 5: E1251.
96. Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, and Silbergeld EK (2003) Variability in human metabolism of arsenic. Environ Res 92:85-91.
97. Lu X, Long Y, Lin L, Sun R, Zhong S, and Cui Z (2014) Characterization of zebrafish Abcc4 as an efflux transporter of organochlorine pesticides. PLoS One 9:e111664.
98. Luo Q, Kang Q, Song WX, Luu HH, Luo X, An N, Luo J, Deng ZL, Jiang W, and Yin H, et al. (2007) Selection and validation of optimal siRNA target sites for RNAimediated gene silencing. Gene 395:160-169.
99. Maeng HJ, Lee WJ, Jin QR, Chang JE, and Shim WS (2014) Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway. Eur J Pharm Sci 62:189-196.
100. Maher JM, Cheng X, Tanaka Y, Scheffer GL, and Klaassen CD (2006) Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice. Biochem Pharmacol 71:1470-1478.
101. Maher JM, Slitt AL, Cherrington NJ, Cheng X, and Klaassen CD (2005) Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos 33:947-955.
102. Markova SM and Kroetz DL (2014) ABCC4 is regulated by microRNA-124a and microRNA-506. Biochem Pharmacol 87:515-522.
103. Martínez T, González MV, Roehl I, Wright N, Pañeda C, and Jiménez AI (2014) In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther 22:81-91.
104. Massimi I, Guerriero R, Lotti LV, Lulli V, Borgognone A, Romani F, Barillà F, Gaudio C, Gabbianelli M, and Frati L, et al. (2014) Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets. Br J Clin Pharmacol 78:1343-1353.
105. Matsumiya W, Kusuhara S, Hayashibe K, Maruyama K, Kusuhara H, Tagami M, Schuetz JD, and Negi A (2012) Forskolin modifies retinal vascular development in Mrp4-knockout mice. Invest Ophthalmol Vis Sci 53:8029-8035.
106. Mattiello T, Guerriero R, Lotti LV, Trifirò E, Felli MP, Barbarulo A, Pucci B, Gazzaniga P, Gaudio C, and Frati L, et al. (2011) Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: Evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 58:752-761.
107. Mizuno N, Takahashi T, Kusuhara H, Schuetz JD, Niwa T, and Sugiyama Y (2007) Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl- 2-pyrazolin-5-one). Drug Metab Dispos 35:2045-2052.
108. Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, and Manautou JE (2006) Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor a. J Pharmacol Exp Ther 317:537-545.
109. Monczor F, Fernandez N, Riveiro E, Mladovan A, Baldi A, Shayo C, and Davio C (2006) Histamine H2 receptor overexpression induces U937 cell differentiation despite triggered mechanisms to attenuate cAMP signalling. Biochem Pharmacol 71:1219-1228.
110. Monteiro N, Branco M, Peres S, Borges F, and Mansinho K (2014) The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIVinfected outpatient cohort. J Int AIDS Soc 17(Suppl 3):19565.
111. Moon C, Zhang W, Ren A, Arora K, Sinha C, Yarlagadda S, Woodrooffe K, Schuetz JD, Valasani KR, and de Jonge HR, et al. (2015) Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea. J Biol Chem 290:11246-11257.
112. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, and Jadoul M (2009) Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: A case of drug-drug interaction. Clin Nephrol 71:567-570.
113. Nakayama T, Mutsuga N, Yao L, and Tosato G (2006) Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J Leukoc Biol 79: 95-104.
114. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, and Chiosi E, et al. (2009) Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther 8:1183-1190.
115. Nornberg BF, Batista CR, Almeida DV, Trindade GS, and Marins LF (2015) ABCB1 and ABCC4 efflux transporters are involved in methyl parathion detoxification in ZFL cells. Toxicol In Vitro 29:204-210.
116. Norris MD, Bordow SB, Haber PS, Marshall GM, Kavallaris M, Madafiglio J, Cohn SL, Salwen H, Schmidt ML, and Hipfner DR, et al. (1997) Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur J Cancer 33: 1911-1916.
117. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, and Haber M (1996) Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231-238.
118. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, and Marshall GM, et al. (2005) Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 4:547-553.
119. Oevermann L, Scheitz J, Starke K, Köck K, Kiefer T, Dölken G, Niessen J, Greinacher A, Siegmund W, and Zygmunt M, et al. (2009) Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer 124:2303-2311.
120. Ozcan G, Ozpolat B, Coleman RL, Sood AK, and Lopez-Berestein G (2015) Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev DOI:10.1016/j.addr.2015.01.007 [published ahead of print].
121. Park J, Kwak JO, Riederer B, Seidler U, Cole SP, Lee HJ, and Lee MG (2014) Na+/H+ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney. J Am Soc Nephrol 25:726-736.
122. Park SW, Kim HS, Choi MS, Jeong WJ, Heo DS, Kim KH, and Sung MW (2011) The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells. J Pharmacol Exp Ther 336:516-523.
123. Pastan IH, Johnson GS, and Anderson WB (1975) Role of cyclic nucleotides in growth control. Annu Rev Biochem 44:491-522.
124. Pattabiraman PP, Pecen PE, and Rao PV (2013) MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure. Invest Ophthalmol Vis Sci 54:1636-1649.
125. Porro A, Haber M, Diolaiti D, Iraci N, Henderson M, Gherardi S, Valli E, Munoz MA, Xue C, and Flemming C, et al. (2010) Direct and coordinate regulation of ATPbinding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 285:19532-19543.
126. Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, and Bernardoni R, et al. (2011) c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD341 hematopoietic progenitor cells. Mol Cancer Res 9:1054-1066.
127. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, and Pozzi A (2007) Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282:16959-16968.
128. Rasmuson A, Kock A, Fuskevåg OM, Kruspig B, Simón-Santamaría J, Gogvadze V, Johnsen JI, Kogner P, and Sveinbjörnsson B (2012) Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 7:e29331.
129. Ravna AW and Sager G (2008) Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorg Med Chem Lett 18:3481-3483.
130. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, and Rhodes GR (2006) Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50:3297-3304.
131. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, and Borst P (2003a) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094-1103.
132. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, and Borst P (2003b) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100:9244-9249.
133. Renga B, MiglioratiM, Mencarelli A, Cipriani S, D'Amore C, Distrutti E, and Fiorucci S (2011) Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta 1809:157-165.
134. Rius M, Hummel-Eisenbeiss J, Hofmann AF, and Keppler D (2006) Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 290:G640-G649.
135. Rius M, Hummel-Eisenbeiss J, and Keppler D (2008) ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J Pharmacol Exp Ther 324:86-94.
136. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:374-384.
137. Rius M, Thon WF, Keppler D, and Nies AT (2005) Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract. J Urol 174:2409-2414.
138. Rivey MP, Alexander MR, and Taylor JW (1984) Dipyridamole: A critical evaluation. Drug Intell Clin Pharm 18:869-880.
139. Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger DM, Ruxrungtham K, Punyawudho B, and Pengsuparp T (2015) Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIVinfected patients. Antimicrob Agents Chemother 59:3240-3245.
140. Russel FG, Koenderink JB, and Masereeuw R (2008) Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29:200-207.
141. Sánchez A, Cabrera S, Santos D, ValverdeMP, Fuertes A, Domínguez-Gil A, and García MJ; Tormes Group (2011) Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother 55:5314-5324.
142. Sassi Y, Abi-Gerges A, Fauconnier J, Mougenot N, Reiken S, Haghighi K, Kranias EG, Marks AR, Lacampagne A, and Engelhardt S, et al. (2012) Regulation of cAMP homeostasis by the efflux proteinMRP4 in cardiac myocytes. FASEB J 26:1009-1017.
143. Sassi Y, Lipskaia L, Vandecasteele G, Nikolaev VO, Hatem SN, Cohen Aubart F, Russel FG, Mougenot N, Vrignaud C, and Lechat P, et al. (2008) Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J Clin Invest 118:2747-2757.
144. Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, and Tamai I (2008) Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25:639-646.
145. Sauna ZE, Nandigama K, and Ambudkar SV (2004) Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: Effect of transport substrates and characterization of the post-hydrolysis transition state. J Biol Chem 279:48855-48864.
146. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, and Komoroski BJ, et al. (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276:39411-39418.
147. Sellers ZM, Naren AP, Xiang Y, and Best PM (2012) MRP4 and CFTR in the regulation of cAMP and b-adrenergic contraction in cardiac myocytes. Eur J Pharmacol 681:80-87.
148. Shayo C, Davio C, Brodsky A, Mladovan AG, Legnazzi BL, Rivera E, and Baldi A (1997) Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Mol Pharmacol 51:983-990.
149. Shayo C, Legnazzi BL, Monczor F, Fernández N, Riveiro ME, Baldi A, and Davio C (2004) The time-course of cyclic AMP signaling is critical for leukemia U-937 cell differentiation. Biochem Biophys Res Commun 314:798-804.
150. Sheng H, Shao J, Morrow JD, Beauchamp RD, and DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362-366.
151. Shimozato T and Kincade PW (1999) Prostaglandin E2 and stem cell factor can deliver opposing signals to B lymphocyte precursors. Cell Immunol 198:21-29.
152. Sinha C, Ren A, Arora K, Moon CS, Yarlagadda S, Woodrooffe K, Lin S, Schuetz JD, Ziady AG, and Naren AP (2015) PKA and actin play critical roles as downstream effectors in MRP4-mediated regulation of fibroblast migration. Cell Signal 27: 1345-1355.
153. Sinha C, Ren A, Arora K, Moon CS, Yarlagadda S, Zhang W, Cheepala SB, Schuetz JD, and Naren AP (2013) Multi-drug resistance protein 4 (MRP4)-mediated regulation of fibroblast cell migration reflects a dichotomous role of intracellular cyclic nucleotides. J Biol Chem 288:3786-3794.
154. Sinha P, Clements VK, Fulton AM, and Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507-4513.
155. Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, and Russel FG (2004) Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol 15:2828-2835.
156. Sodani K, Patel A, Kathawala RJ, and Chen ZS (2012) Multidrug resistance associated proteins in multidrug resistance. Chinese J Cancer 31:58-72.
157. Southgate K and Newby AC (1990) Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 82:113-123.
158. Sun Y, Shi N, Lu H, Zhang J, Ma Y, Qiao Y, Mao Y, Jia K, Han L, and Liu F, et al. (2014) ABCC4 copy number variation is associated with susceptibility to esophageal squamous cell carcinoma. Carcinogenesis 35:1941-1950.
159. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
160. Tagami M, Kusuhara S, Imai H, Uemura A, Honda S, Tsukahara Y, and Negi A (2010) MRP4 knockdown enhances migration, suppresses apoptosis, and produces aggregated morphology in human retinal vascular endothelial cells. Biochem Biophys Res Commun 400:593-598.
161. Tanaka Y, Manabe A, Fukushima H, Suzuki R, Nakadate H, Kondoh K, Nakamura K, Koh K, Fukushima T, and Tsuchida M, et al. (2014) Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J DOI:10.1038/tpj.2014.74 [published ahead of print].
162. Tian Q, Zhang J, Chan SY, Tan TM, Duan W, Huang M, Zhu YZ, Chan E, Yu Q, and Nie YQ, et al. (2006) Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 7:105-118.
163. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, and Bian JS, et al. (2005) Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22:1837-1853.
164. Tong WG, Ding XZ, Talamonti MS, Bell RH, and Adrian TE (2005) LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335:949-956.
165. Uchida Y, Kamiie J, Ohtsuki S, and Terasaki T (2007) Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 24:2281-2296.
166. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
167. Van Aubel RA, Smeets PH, van den Heuvel JJ, and Russel FG (2005) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288:F327-F333.
168. van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, Jansen G, Gillet JP, Glasgow JN, Pereboev A, and Curiel DT, et al. (2008) A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 112: 2353-2359.
169. Van Keymeulen A, Deleu S, Bartek J, Dumont JE, and Roger PP (2001) Respective roles of carbamylcholine and cyclic adenosine monophosphate in their synergistic regulation of cell cycle in thyroid primary cultures. Endocrinology 142:1251-1259.
170. Ventimiglia MS, Najenson AC, Perazzo JC, Carozzo A, Vatta MS, Davio CA, and Bianciotti LG (2015) Blockade of multidrug resistance-associated proteins aggravates acute pancreatitis and blunts atrial natriuretic factor's beneficial effect in rats: Role of MRP4 (ABCC4). Mol Med 21:58-67.
171. Wallace AE, Sales KJ, Catalano RD, Anderson RA, Williams AR, Wilson MR, Schwarze J, Wang H, Rossi AG, and Jabbour HN (2009) Prostaglandin F2a-F-prostanoid receptor signalling promotes neutrophil chemotaxis via chemokine (CXC motif) ligand-1 in endometrial adenocarcinoma. Cancer Res 69:5726-5733.
172. Wang D, Buchanan FG, Wang H, Dey SK, and DuBois RN (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65:1822-1829.
173. Wang D and Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181-193.
174. Wang D and DuBois RN (2013) An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J 19:502-510.
175. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, and DuBois RN (2006) CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203:941-951.
176. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, and DuBois RN (2004) Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor d. Cancer Cell 6:285-295.
177. Wang L, Cao XX, Chen Q, Zhu TF, Zhu HG, and Zheng L (2009) DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci 100:1801-1808.
178. Wang Z, Xu Y, Meng X, Watari F, Liu H, and Chen X (2015) Suppression of c-Myc is involved in multi-walled carbon nanotubes' down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells. Toxicol Appl Pharmacol 282:42-51.
179. Ward AC, Csar XF, Hoffmann BW, and Hamilton JA (1996) Cyclic AMP inhibits expression of D-type cyclins and cdk4 and induces p27Kip1 in G-CSF-treated NFS-60 cells. Biochem Biophys Res Commun 224:10-16.
180. Welch MA, Kock K, Urban TJ, Brouwer KL, and Swaan PW (2015) Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors. Drug Metab Dispos 43: 725-734.
181. Wittgen HG, van den Heuvel JJ, van den Broek PH, Siissalo S, Groothuis GM, de Graaf IA, Koenderink JB, and Russel FG (2012) Transport of the coumarin metabolite 7-hydroxycoumarin glucuronide is mediated via multidrug resistanceassociated proteins 3 and 4. Drug Metab Dispos 40:1076-1079.
182. Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, and Barrand MA (2005) Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 272:4725-4740.
183. Xu S, Weerachayaphorn J, Cai SY, Soroka CJ, and Boyer JL (2010) Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol 299:G126-G135.
184. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, and Schuetz JD, et al. (2007) Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35: 2166-2176.
185. Yu Z, Zhang C, Chai R, Du Y, Gao X, Xing J, Yu E, Zhang W, Zhang X, and Cao G, et al. (2014) Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma. PLoS One 9:e85446.
186. Zambon AC, Zhang L, Minovitsky S, Kanter JR, Prabhakar S, Salomonis N, Vranizan K, Dubchak I, Conklin BR, and Insel PA (2005) Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA 102:8561-8566.
187. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, Vaishnaw A, Cehelsky J, Albert G, and Nochur S, et al. (2011) RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 183:531-538.
188. Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, and Borst P (2003) Steroid and bile acid conjugates are substrates of human multidrugresistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 371:361-367.
189. Zhang YH, Wu Q, Xiao XY, Li DW, and Wang XP (2010) Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett 291:76-82.
190. Zhang Z, Wang J, Shen B, Peng C, and Zheng M (2012) The ABCC4 gene is a promising target for pancreatic cancer therapy. Gene 491:194-199.
191. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, and Yavin E, et al. (2013) Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA 110:20723-20728.
192. Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, and Reinhardt D, et al. (2013) Dasatinib in children and adolescents with relapsed or refractory leukemia: Results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 31:2460-2468.